TempraMed has amended its exclusive distribution agreement with TEM Consulting to expand beyond Panama into six additional Latin American countries, adding VIVI Med™ to its product line. This expansion covers Argentina, Venezuela, Colombia, Costa Rica, Mexico, and Brazil, aiming to reach over 70% of the region's population. TempraMed received a new commercial order from TEM, expected to be fulfilled by September 2026, and plans a non-brokered private placement to raise up to C$1 million to support inventory, product development, and global sales expansion. This move strengthens TempraMed's presence in Latin America, targeting temperature-sensitive medication markets in hot climates with practical, battery-free storage solutions.
TempraMed's expansion in Latin America coincides with a health sector market where 22 of 100 US stocks rose and 75 fell on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Sep 24, 2026 12:41 WIB: DNA (Ginkgo Bioworks Holdings Inc) traded at USD 8.59 with a 1-day change of -8.32% and a typical hold time of 10 days, showing 70% sell order activity; BNGO (BioNano Genomics Inc) at USD 1.67 with -8.24% change and 49 days hold time, with 93% sell orders; and SANA (Sana Biotechnology Inc) at USD 3.09 with -7.21% change and 22 days hold time, but 93% buy orders.
SpaceX is ineligible to join the S&P 500 index before June 2027 because of the index's listing rules, which include a minimum time as a public company. Additionally, SpaceX's current financial losses may delay its inclusion further. This means invest...
Since Bitcoin reached its all-time high, only 9 out of the 50 largest altcoins by market cap have outperformed Bitcoin. ZEC showed the strongest performance, returning 14 times more than Bitcoin during this period. Other notable altcoins like HYPE, X...
Ethereum fell 2.84% to around $2,670 on September 23 after facing selling pressure near $2,789, marking a pullback from its mid-September rally that started near $2,400. Despite the decline, ETH remains above key moving averages, signaling underlying...
Applied Aerospace & Defense (AADX) shares have fallen about 37% below their $20 IPO price since June, now trading near $12.69, creating a buying opportunity. The IPO reduced the company's net leverage, improving financial flexibility for growth and a...
Nike Inc. will report its first-quarter fiscal 2027 results on October 1, with analysts forecasting a 3.2% decline in revenue to $11.3 billion compared to last year. The sales drop is mainly due to weak performance in Greater China and the Europe, Mi...
